NEW YORK--(EON: Enhanced Online News)--Levi & Korsinsky announces it has commenced an investigation of Stemline Therapeutics, Inc. (NASDAQ:STML) concerning possible violations of federal securities laws.
On January 19, 2017, Stemline announced its proposed public Offering. Then on February 2, 2017, Bloomberg reported that a patient in a clinical trial of the Company’s cancer drug SL-401 died from a severe side effect—the third death linked to the same SL-401 toxicity. Upon this news, shares of Stemline were down more than 37% on intraday trading on February 2, 2017. A report from TheStreet.com indicates that one of the patient deaths occurred on January 18, 2017, and was not disclosed to investors who bought shares pursuant to the Offering. Upon this news, shares of Stemline were down more than 38% on intraday trading on February 2, 2017. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.